Business review P08P57 Governance and remuneration P58P101 Financial statements P102P191 Shareholder information P192P212 21 GSK sales performance GSK delivered underlying sales growth excluding pandemic related products, Avandia and Valtrex for 2010 of 4.5% despite the ongoing impacts of EU government austerity measures and US healthcare reform which reduced sales by approximately 380 million.
Commentary on GSKs segmental sales performance uses the performance measures set out below.
Underlying sales growth Underlying sales growth excludes the sales of pandemic products, Avandia and Valtrex.
Management believes this measure assists shareholders in gaining a clearer understanding of the Groups sales performance and prospects because of the size and nature of the loss of sales from these products.
A reconciliation to Group and pharmaceutical turnover is as follows: 2010 2009 Growth m m CER% Group turnover 28,392 28,368 1.2 Avandia, Valtrex and pandemic products 2,285 3,668 Underlying Group turnover 26,107 24,700 4.5 2010 2009 Growth m m CER% Pharmaceutical turnover 23,382 23,694 2 Avandia, Valtrex and pandemic products 2,285 3,668 Underlying pharmaceutical turnover 21,097 20,026 4 Sales of these products by segment were: Emerging Asia Pacic Other trading USA Europe Markets Japan and unallocated Total 2010 m m m m m m Pandemic products 44 494 227 462 86 1,313 Avandia 237 88 42 24 49 440 Valtrex 252 68 28 176 8 532 Emerging Asia Pacic Other trading USA Europe Markets Japan and unallocated Total 2009 m m m m m m Pandemic products 324 737 89 331 122 1,603 Avandia 425 171 76 41 58 771 Valtrex 942 160 26 152 14 1,294 White pills western markets White pills western markets refers to sales of tablets and simple injectables excluding biopharmaceuticals and vaccines in North America and Europe.
CER growth In order to illustrate underlying performance, it is the Groups practice to discuss its results in terms of constant exchange rate CER growth.
This represents growth calculated as if the exchange rates used to determine the results of overseas companies in Sterling had remained unchanged from those used in the previous year.
CER% represents growth at constant exchange rates.
% represents growth at actual exchange rates.
All commentaries in this Report are presented in terms of CER unless otherwise stated.
